Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Nephrology Section, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, European Kidney Health Alliance.
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1669-1677. doi: 10.2215/CJN.14961219. Epub 2020 Jun 25.
Contemporary dialysis treatment for chronic kidney failure is complex, is associated with poor clinical outcomes, and leads to high health costs, all of which pose substantial policy challenges. Despite similar policy goals and universal access for their kidney failure programs, the United States and Canada have taken very different approaches to dealing with these challenges. While US dialysis care is primarily government funded and delivered predominantly by private for-profit providers, Canadian dialysis care is also government funded but delivered almost exclusively in public facilities. Differences also exist for regulatory mechanisms and the policy incentives that may influence the behavior of providers and facilities. These differences in health policy are associated with significant variation in clinical outcomes: mortality among patients on dialysis is consistently lower in Canada than in the United States, although the gap has narrowed in recent years. The observed heterogeneity in policy and outcomes offers important potential opportunities for each health system to learn from the other. This article compares and contrasts transnational dialysis-related health policies, focusing on key levers including payment, finance, regulation, and organization. We also describe how policy levers can incentivize favorable practice patterns to support high-quality/high-value, person-centered care and to catalyze the emergence of transformative technologies for alternative kidney replacement strategies.
当代慢性肾衰竭的透析治疗较为复杂,与较差的临床结局相关,并导致高昂的卫生保健费用,所有这些都对政策制定提出了重大挑战。尽管美加两国的肾衰竭项目具有相似的政策目标和全民覆盖,但在应对这些挑战方面却采取了非常不同的方法。在美国,透析护理主要由政府提供资金,并主要由私营营利性供应商提供;而在加拿大,透析护理同样由政府提供资金,但几乎完全在公立机构中提供。监管机制和政策激励措施方面也存在差异,这些差异可能会影响提供者和医疗机构的行为。这些卫生政策的差异与临床结局的显著差异相关:接受透析治疗的患者的死亡率在加拿大一直低于美国,尽管近年来差距有所缩小。政策和结果的这种异质性为每个卫生系统相互学习提供了重要的潜在机会。本文比较和对比了跨国透析相关的卫生政策,重点关注包括支付、融资、监管和组织在内的关键杠杆。我们还描述了政策杠杆如何激励有利的实践模式,以支持高质量/高价值、以患者为中心的护理,并推动替代肾脏替代策略的变革性技术的出现。